Literature DB >> 12091848

Efficacy, tolerability, and kinetics of lamotrigine in infants.

Mohamad A Mikati1, Michel Fayad, Majed Koleilat, Nabil Mounla, Rania Hussein, Alia Kazma, Khalid Yunis.   

Abstract

OBJECTIVES: To investigate the efficacy, tolerability, and kinetics of lamotrigine during the first year of life. STUDY
DESIGN: We studied 13 infants with intractable seizures; 7 had partial seizures and 7 had infantile spasms (1 had both). Patients received open-label lamotrigine as add-on therapy for 3 months. Seizure frequency, response ratio, and side effects score were determined and compared with the baseline period.
RESULTS: The rate of partial seizures per day decreased from 8.57 +/- 2.29 to 4.00 +/- 2.15 (P =.027) and infantile spasms from 8.71 +/- 2.15 to 3.61 +/- 2.762 (P =.028). Apparent clearance increased during the first year of life, with a break point at 2 months of age (mean, 0.119 +/- 0.021, 0.217 +/- 0.094 L/h per kilogram for infants <2 months and those 2 to 12 months old, respectively,P <.001). Twenty-four-hour concentration to time plots of three 3- to 4-week-old neonates showed a half-life of 23.44 +/- 3.57 hours. Compared with a group of 17 older children, LTG had similar efficacy (response ratios, -0.68 +/- 0.12 and -0.74 +/- 0.11, P =.504), and similar adverse effects scores (0.67 +/- 0.67 and 0.23 +/- 0.166, P =.95).
CONCLUSIONS: Lamotrigine is a useful and well tolerated drug for partial seizures and infantile spasms in infants <1 year of age. However, lamotrigine has age-dependent kinetics that must be taken into consideration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12091848     DOI: 10.1067/mpd.2002.125256

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  15 in total

Review 1.  Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.

Authors:  Maria D Donovan; Geraldine B Boylan; Deirdre M Murray; John F Cryan; Brendan T Griffin
Journal:  Br J Clin Pharmacol       Date:  2015-11-04       Impact factor: 4.335

2.  Authors' Reply to Standing et al.: "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials".

Authors:  Sven C van Dijkman; Nico C B de Jager; Willem M Rauwé; Meindert Danhof; Oscar Della Pasqua
Journal:  Clin Pharmacokinet       Date:  2018-11       Impact factor: 6.447

Review 3.  Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?

Authors:  Svein I Johannessen; Torbjörn Tomson
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Newer anticonvulsant medications in pediatric neurology.

Authors:  Michael M Quach; Abdul Mazin; James J Riviello
Journal:  Curr Treat Options Neurol       Date:  2010-11       Impact factor: 3.598

Review 5.  The safety and tolerability of newer antiepileptic drugs in children and adolescents.

Authors:  Dean P Sarco; Blaise F D Bourgeois
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

Review 6.  Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age.

Authors:  Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 7.  Use of second-generation antiepileptic drugs in the pediatric population.

Authors:  Allison M Chung; Lea S Eiland
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

8.  Lamotrigine in breast milk and nursing infants: determination of exposure.

Authors:  D Jeffrey Newport; Page B Pennell; Martha R Calamaras; James C Ritchie; Melanee Newman; Bettina Knight; Adele C Viguera; Joyce Liporace; Zachary N Stowe
Journal:  Pediatrics       Date:  2008-06-30       Impact factor: 7.124

Review 9.  Pharmacotherapy for Neonatal Seizures: Current Knowledge and Future Perspectives.

Authors:  Maria D Donovan; Brendan T Griffin; Liudmila Kharoshankaya; John F Cryan; Geraldine B Boylan
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

10.  Neuroprotection of lamotrigine on hypoxic-ischemic brain damage in neonatal rats: Relations to administration time and doses.

Authors:  Yong-Hong Yi; Wen-Chao Guo; Wei-Wen Sun; Tao Su; Han Lin; Sheng-Qiang Chen; Wen-Yi Deng; Wei Zhou; Wei-Ping Liao
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.